Craft
  • Home
  •  / Entasis Therapeutics
Entasis Therapeutics

Entasis Therapeutics

Revenue

$7 M

FY, 2019

Market Capitalization

$104.3 M

2022-07-11

Entasis Therapeutics Summary

Company summary

Overview
Entasis Therapeutics is a pharmaceutical company developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. The Company has developed a robust clinical and pre-clinical pipeline of first- and best-in-class medicines, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
Type
Public
Founded
2015
HQ
Waltham, MA, US | view all locations
Website
http://www.entasistx.com/
Cybersecurity rating
Sectors

Key people

  • David Meek

    David Meek, Chairman

    • Manos Perros

      Manos Perros, President and Chief Executive Officer, Director

    • Michael Gutch

      Michael Gutch, Chief Business Officer / Chief Financial Officer

      • David Altarac

        David Altarac, Chief Medical Officer

        LocationsView all

        1 location detected

        • Waltham, MA HQ

          United States

          35 Gatehouse Dr

        Entasis Therapeutics Financials

        Summary financials

        Net income (Q1, 2022)
        ($15.3M)
        Cash (Q1, 2022)
        $33.5M
        EBIT (Q1, 2022)
        ($15.9M)

        Footer menu